title: Prognostic Factors in Stage III Non-Small-Cell Lung Cancer
  Patients
abstract: Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing
  concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and
  materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III
  NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and
  3-year overall survival was 27%. Age (<65 vs ≥65 years, p=0.026), stage (IIIA vs IIIB, p=0.033), dose of radiotherapy
  (RT) (<60 vs ≥60 Gy, p=0.024) and treatment method (sequential chemotherapy+RT vs concurrent CRT , p=0.023)
  were found to be factors affecting survival in univariate analyses. Gender, histological subtype, weight loss during
  CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival
  (p>0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively
  affect survival in stage III NSCL cases.
authors.affiliation: Acıbadem Hospitals Group, Birsen Yücel, Kayseri, Turkey. Email: semiha.urvay@acibadem.gov.tr
authors.forename: Semiha Elmaci
authors.initials: SE
authors.lastname: Urvay
authors.forename: Birsen
authors.initials: B
authors.lastname: Yucel
authors.forename: Eda
authors.initials: E
authors.lastname: Erdis
authors.forename: Nedim
authors.initials: N
authors.lastname: Turan
keywords: Non-small lung cancer; prognostic factors; survival